Universal Biosensors Inc. (ASX:UBI)


right-arrow Created with Sketch. -0.005 (-0.51%)
MCAP $173.3M
Last trade 11.37am 19/01/2022 20mins delayed

Latest Announcements

18/01/2022 Price SensitivePSUBIUniversal Biosensors Inc.
24/12/2021 Price SensitivePSUBIUniversal Biosensors Inc.
17/12/2021UBIUniversal Biosensors Inc.
17/12/2021UBIUniversal Biosensors Inc.
17/12/2021UBIUniversal Biosensors Inc.
19/11/2021UBIUniversal Biosensors Inc.
12/11/2021UBIUniversal Biosensors Inc.
11/11/2021 Price SensitivePSUBIUniversal Biosensors Inc.

Company Overview

Universal Biosensors, Inc. is a biosensors company primarily focused on the development, manufacture and commercialization of a range of point-of-use devices for measuring different analytes across different industries. The Company operates through Universal Biosensors Pty Ltd (UBS) and Hemostasis Reference Laboratory Inc. (HRL) subsidiaries. UBS is the manufacturer and distributor of Prothrombin Time International Normalized Ratio (PT-INR) coagulation test strips and the distributor of the Siemens’ Xprecia Stride coagulation analyzer. HRL conducts coagulation testing and calibration services. The Company is also focused on the Sentia Wine Analyzer test, which is used to test for free Sulphur Dioxide. The Company uses its electrochemical cell technology platform to develop point-of-care testing systems for a range of different markets. It has developed a blood glucose test with LifeScan, Inc. and a coagulation PT-INR test with Siemens Healthcare Diagnostics Inc.

UBI in the news

Universal Biosensors (UBI) has entered into a global exclusive licence agreement with…
Universal Biosensors (UBI) enters into a collaboration agreement with Mayo Clinic Biopharma…
Universal Biosensors (UBI) enters into a non-exclusive distribution deal with Vivelys SAS…
Universal Biosensors (UBI) signs an agreement with Peter MacCallum Cancer Centre for…

Search Previous Announcements